YIH
RLAY icon

Y-Intercept (HK)’s Relay Therapeutics RLAY Stock Holding History

Y-Intercept (HK)’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-17,516
Closed -$174K – 2092
2026
Q1 		$174K Buy
+17,516
New +$157K ﹤0.01% 1446
2024
Q4 		– Sell
-51,856
Closed -$367K – 1582
2024
Q3 		$367K Buy
+51,856
New +$387K 0.02% 927

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Y-Intercept (HK)'s RLAY Position: Q2 2026 in Review

Y-Intercept (HK) sold out of Relay Therapeutics (RLAY) in Q2 2026, closing a stake of 17,516 shares — an estimated $174K sold.

Y-Intercept (HK) first reported a position in RLAY in Q3 2024 and held it in 2 quarters. The position peaked at $367K in Q3 2024. 260 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Y-Intercept (HK) reported no remaining Relay Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Y-Intercept (HK) sold 17,516 Relay Therapeutics shares in Q2 2026, an estimated $174K.
  • Y-Intercept (HK) first reported a position in Relay Therapeutics in Q3 2024 and held it in 2 quarters.
  • Y-Intercept (HK)'s Relay Therapeutics position peaked at $367K in Q3 2024.
  • 260 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.